Search Results

Rakuten Medical, Inc. announced the updated safety and efficacy findings from an interim evaluation of an open-label Phase 1b/2 study of photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma.

NewAmsterdam Pharma Company N.V. announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.

Precision BioSciences, Inc. is presenting data today at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that it intends to offer and sell shares of its common stock and/or pre-funded warrants in an underwritten public offering.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase (“IDH”) 1 or 2 relapsed / refractory acute myeloid leukemia (“AML”) in China. The first patient received their first dose on May 11, 2024.

As part of National Women’s Health Week, Evidation and Myovant Sciences Ltd., a wholly owned subsidiary of Sumitovant Biopharma Ltd. announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

NewAmsterdam Pharma Company N.V. announced the completion of patient enrollment in the pivotal Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia and/or established atherosclerotic cardiovascular disease, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

Antengene Corporation Limited announced that the Pharmaceutical Administration Bureau of Macau has approved a New Drug Application for XPOVIO®.

A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc., a leader in genetic testing and precision medicine.